BioAtla, Inc. (BCAB)
NASDAQ: BCAB · Real-Time Price · USD
0.824
-0.024 (-2.85%)
At close: Dec 5, 2025, 4:00 PM EST
0.850
+0.026 (3.17%)
After-hours: Dec 5, 2025, 7:49 PM EST
BioAtla Employees
BioAtla had 61 employees as of December 31, 2024. The number of employees decreased by 4 or -6.15% compared to the previous year.
Employees
61
Change (1Y)
-4
Growth (1Y)
-6.15%
Revenue / Employee
n/a
Profits / Employee
-$1,060,770
Market Cap
48.43M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 61 | -4 | -6.15% |
| Dec 31, 2023 | 65 | -1 | -1.52% |
| Dec 31, 2022 | 66 | 10 | 17.86% |
| Dec 31, 2021 | 56 | 20 | 55.56% |
| Dec 31, 2020 | 36 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BCAB News
- 15 days ago - BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing - GlobeNewsWire
- 22 days ago - BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress - GlobeNewsWire
- 4 weeks ago - BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas - GlobeNewsWire
- 4 weeks ago - BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025 - GlobeNewsWire
- 6 weeks ago - BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society - GlobeNewsWire
- 6 weeks ago - BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025 - GlobeNewsWire
- 2 months ago - BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025 - GlobeNewsWire